Four places to go. Start with what real-world data actually is if the term is new to you, go to the twelve data types if you want to know what each one can answer, read the case studies if you want to see the work, and open the Content Hub if you want the running argument.
The plain guide. What real-world data is, how evidence is generated from it, how it differs from a clinical trial, what every data type contains, and which questions each one can and cannot answer.
Start here if the terminology is new, or if you need something to send an internal stakeholder who keeps using the two terms interchangeably.
Every real-world data type in plain English, with every acronym spelled out. What each one is, what it is genuinely good at, what it cannot tell you, and the questions it answers for a pharma team.
The reference page. Most clients end up sending this one to a colleague.
Six worked examples of the questions Asia-Pacific real-world data can answer, the shape of the work behind each, and where each one stops being defensible.
Labelled as illustrative, because they are composites rather than named client engagements.
A running archive of practitioner writing on real-world data access in Asia-Pacific, healthcare data governance, speed to evidence, and what is possible market by market. Named author, dated, no committee prose.
Thirty-three pieces across six standing themes, in two formats, with nothing taken down.
Most of what a buyer needs to know before commissioning real-world evidence is not commercially sensitive. It is just hard to find in one place, written by someone who has actually negotiated access rather than summarised a vendor brochure.
Putting it here means the first conversation starts from a shared understanding rather than from a capability presentation. That is better for you, and frankly it is better for us, because the questions we get are sharper.
We will tell you whether the data can answer it, in which market, and how long it will take.
